Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line chemotherapy for patients with ovarian cancer, ...

Bevacizumab addition to chemotherapy showed significant progression-free survival benefits in high-risk epithelial ovarian cancer patients but not in overall survival. The BEV1L study used real-world ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line chemotherapy for patients with ovarian cancer, ...

High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...

Using national Medicare data, we performed retrospective analyses of beneficiaries who had a new cancer diagnosis between 2016 and 2021 and who were at risk of receiving a low-value treatment: ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...

Ovarian cancer (OC) remains the deadliest gynecologic malignancy, with platinum-based chemotherapies such as carboplatin serving as the standard first-line treatment. However, the emergence of ...

The powerhouse drug Avastin may be linked to severe kidney problems. June 11, 2010 -- Patients taking the anti-cancer drug Avastin may increase their risk of kidney damage, a new study says -- but ...